Indaptus raises $2.3M via convertible notes and warrants; up to $5M total

Indaptus Therapeutics, Inc.

$2.3M aggregate principal of 6% convertible promissory notes; mature July 28, 2026.
Conversion at 80% of 5-day VWAP, max $0.40; warrants for 200% of conversion shares after approval.
Net proceeds for R&D, Phase 1b/2 trial funding, and general working capital.
Offering may increase to $5M; Paulson Investment Company is exclusive placement agent with 12% fee.
Company must hold special meeting for stockholder approval; note conversion tied to reverse split or 1 year.

item 1.01item 2.03item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.